BRISBANE, Calif. — October 3, 2025 — Leads & Copy — Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the granting of inducement awards to 15 new employees on October 2, 2025, under Pacira’s Amended and Restated 2014 Inducement Plan, as a material inducement to their employment with the company.
The awards, approved by the People & Compensation Committee of the Board of Directors without stockholder approval, were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Six employees received stock options to purchase 18,000 shares of Pacira common stock, and 15 employees received restricted stock units for 32,600 shares. The stock options have a 10-year term and a four-year vesting schedule, with an exercise price of $24.58 per share. The restricted stock unit awards vest annually in four equal installments beginning on October 1, 2026. Vesting is subject to continued employment with Pacira.
Pacira BioSciences, Inc. delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º. The Company is also advancing the development of PCRX-201.
Investor Contact: Susan Mesco, (973) 451-4030, susan.mesco@pacira.com
Media Contact: Sara Marino, (973) 370-5430, sara.marino@pacira.com
Source: Pacira BioSciences, Inc.
